2 completed, 2 terminated, 1 active not recruiting. 5 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 2, Terminated 2, Active not recruiting 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Stage III Breast Cancer: new trials by email Literature Review of Stage III Breast Cancer trials Research Report on Stage III Breast Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer Atezolizumab, Cobimetinib, Idasanutlin - Stage III Breast Cancer, Stage IIIA Breast Cancer | Phase 1 / Phase 2 | Terminated | Vanderbilt-Ingram Cancer Center | 12 | 2018-07-10 | 2021-08-11 |
| 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer Utomilumab, Trastuzumab, Ado-Trastuzumab Emtansine - HER2 Positive Breast Carcinoma, Recurrent Breast Carcinoma | Phase 1 | Completed | George W. Sledge Jr. | 18 | 2017-10-30 | 2022-10-19 |
| Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer Biopsy of Breast, Copanlisib, Laboratory Biomarker Analysis - Estrogen Receptor Positive, HER2/Neu Negative | Phase 1 | Terminated | Jonsson Comprehensive Cancer Center | 10 | 2017-08-02 | 2022-09-26 |
| Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission Laboratory Biomarker Analysis, pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine, Sargramostim - HER2/Neu Negative, No Evidence of Disease | Phase 1 | Completed | University of Washington | 32 | 2016-09-02 | 2024-09-19 |
| Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Laboratory Biomarker Analysis - HER2 Negative Breast Carcinoma, Recurrent Breast Carcinoma | Phase 1 | Active not recruiting | University of Washington | 42 | 2015-06-01 | 2026-02-17 |
Breast Neoplasms (5)
Breast Diseases (5) · Neoplasms (5) · Neoplasms by Site (5) · Skin Diseases (5) · Skin and Connective Tissue Diseases (5)
Ado-Trastuzumab Emtansine (1) · Colony-Stimulating Factors (1) · Letrozole (1) · PF-05280014 (1) · RG7388 (1) · Trastuzumab (1) · atezolizumab (1) · cobimetinib (1) · copanlisib (1) · palbociclib (1) · sargramostim (1) · utomilumab (1)
University of Washington (2) · George W. Sledge Jr. (1) · Jonsson Comprehensive Cancer Center (1) · Vanderbilt-Ingram Cancer Center (1)
United States (5)
George Sledge, MD (1) · Ingrid Mayer, MD (1) · Kari Wisinski (1) · Mary Disis (1) · Sara Hurvitz (1)
N01CN00033 (1), P30CA014520 (1)